Acetylfentanyl, N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, is an analogue of the potent opioid analgesic fentanyl.It may also be referred to as nonpharmaceutical fentanyl. Some common street names for acetyl fentanyl include China White, Apache, China girl, dance fever, friend, goodfella, jackpot, murder 8, TNT, and Tango and Cash. The chemical structure of acetyl fentanyl is very similar to fentanyl’s. The substance is also referred to as desmethyl fentanyl because of a missing methyl group in its structure compared to that of fentanyl. Acetyl fentanyl is manufactured, distributed, and sold illicitly, and may be mixed with heroin or other agents. They may market it as heroin, oxycodone (OxyContin), or fentanyl to unsuspecting buyers. Fentanyl is 50 to 100 times more potent than morphine. When mixed with other substances, such as heroin, it can have additive toxic effects.
According to the CDC’s Health Alert Network, some states have reported a rise in fatalities associated with acetyl fentanyl since 2012. There have been reports of over 700 overdose deaths attributed to fentanyl and acetyl fentanyl from 2013 to 2014. It is conceivable that the number is much higher, since some state health departments are reporting even greater numbers, particularly in the eastern United States. Ohio reported 514 overdoses in 2014, and Maryland reported 185. In addition, most medical examiners do not test for acetyl fentanyl unless specifically asked to do so. Data from the National Forensic Laboratory Information System reported an increase in the number of drug seizures in some states for acetyl fentanyl from 618 in 2012 to 4,585 in 2014.
Acetyl fentanyl, like fentanyl, binds to mu opioid receptors, causing agonist effects. Studies suggest that its potency is 5 to 15 times that of heroin. Clinical effects are like those of other opioid agents, including analgesia, as well as euphoria, altered mood, miosis, drowsiness, cough suppression, decreased gastro-intestinal motility, and respiratory depression. Adverse effects of fentanyl may include nausea, itching, dizziness, or altered mental status, and may progress to more severe toxicity.
Tolerance and Dependence
Similar to other opioid agents, repeated use can lead to tolerance, with escalating doses required for an effect. Acetyl fentanyl may also serve as a substitute for heroin or other opioids in opioid-dependent persons, because of agonism of the same mu opioid receptors. Individuals may believe they are using heroin and inadvertently become tolerant to or dependent on the more potent opioid, such that a return to unadulterated heroin no longer provides the expected effects. While we has not specifically described withdrawal, given its affinity for opioid receptors, an opioid withdrawal pattern would be expected, with anxiety, sweating, abdominal discomfort, nausea/vomiting, diarrhea, shivering, and piloerection.
Clinical studies evaluating the pharmacologic effects of acetyl fentanyl specifically in humans are lacking. Its toxicity is like that of other opioids, with lethargy progressing to coma, respiratory depression leading to apnea, bradycardia, and hypotension.11,12 Death is usually because of respiratory arrest. Users may be at greater risk of severe effects if they believe they are using heroin but have actually purchased the more potent acetyl fentanyl or a mixture of the two.
The effects of acetyl fentanyl can be potentiated by other central nervous system (CNS) depressants, including other opioids. When it is used with alcohol, synergistic effects occur. Benzodiazepines also have an additive and possibly synergistic effect on CNS and respiratory depression. When these are taken with stimulants, rapid respiratory depression may ensue at the point that the stimulant properties resolve. Use of HIV protease inhibitors, such as ritonavir, may reduce the elimination of acetyl fentanyl and increase plasma levels.
The CDC recommends testing using enzyme-linked immuno-sorbent assay (ELISA) for those patients showing symptoms consistent with opioid overdose. If the test is positive, we recommend confirmatory testing using gas chromatography–mass spectrometry (GC-MS) testing on specimens to confirm or rule out fentanyl and its analogues, including acetyl fentanyl.
Treatment With Naloxone
Pharmacists should counsel patients, family members, and caregivers to become familiar with signs of opioid overdose as well as to understand the instructions for administering a reversal agent. Opiate overdose should be sus-pected in any patient presenting with the triad of mental status depression, miosis, and respiratory depression. In the nonhospital setting, something should contact immediately 911.
Naloxone is an opioid receptor antagonist showed for the treat-ment of respiratory depression (overdose) due to an opioid agent, including fentanyl derivatives such as acetyl fentanyl. It is FDA-approved for use in opioid reversal. Ready access to this medication can save lives
Naloxone is available in several dosage forms, including IV, injectable (IM/SC), and nasal spray. Typical starting doses are 0.1 to 0.2 mg IV. Onset is rapid, within minutes if not faster. If we see no response, the dose may be repeated or increased every 2 to 3 minutes until respiratory status improves. Due to the potency of acetyl fentanyl, doses of 2 to 5 mg or more may be required.
Some forms of naloxone are now available for use outside of clinical settings for overdose management. Evzio is a kit with two prefilled, single-use, auto-injectors of 0.4 mg/0.4 mL of naloxone, for IM or SC use only. The instructions include print and an electronic voice tutorial on how to administer the drug.
Naloxone is also available for intranasal administration for use outside of clinical settings. Narcan nasal spray is a kit with two single-use 4 mg/0.1 mL doses of naloxone.19 In addition, naloxone has been administered off-label intranasally via atomizer at doses of 2 mg.
Naloxone may precipitate withdrawal in the setting of lower potency opioids or high doses, characterized by anxiety, sweating, abdominal discomfort, diarrhea, shivering, and piloerection. If respiratory depression is not present or has reversed, additional naloxone is not indicated, as other agents could contribute to CNS depression, and concomitant withdrawal could be detrimental. The effects of naloxone last 30 to 90 minutes, and may abate while long-acting opiate drugs (including fentanyl derivatives) are still present, resulting in recurrent symptoms that may require treatment.21 Thus, all patients should be observed in a healthcare facility beyond the effects of naloxone. Patients who receive naloxone should be cautioned to avoid opiates until the naloxone has been cleared, as they may not feel an initial effect due to receptor blockade and then suddenly become symptomatic.
Additional treatment hinges on supportive care, including cardiopulmonary support and resuscitation. The use of naloxone does not prevent ongoing respiratory assistance while awaiting a response. Intubation and mechanical ventilation may be required in patients with no response to naloxone, particularly when cointoxicants are considered or the picture is unclear.
Acetyl fentanyl and other new psychoactive substances (NPS), as referenced by the United Nations Office on Drugs and Crime,22 are sold primarily through the Internet, in head shops, and on the street as “legal.” These products are often labeled “not for human consumption” to skirt state and federal laws in the U.S. Acetyl fentanyl and other NPS pose a significant regulatory challenge at both the federal and the state level because the products are continually morphing chemically to evade regulations.
State Regulations: States have had to learn to be creative in combating the regulatory challenges posed by NPS. According to the National Conference of State Legislatures, most states are using either individual bans, general bans to prohibit synthetic drugs, or analogue laws. Analogue laws rely on banning substances based on the substance having properties chemically similar to a regulated Schedule I or II drug. Some states also delegate administrative authority to the state’s board of pharmacy to ban NPS or place them in a Schedule I category until legislative action can be taken. States have also used agricultural laws or “nuisance abatement laws” to combat sale and distribution.27 Currently, 34 states use analogue laws to ban NPS according to the National Alliance for Model State Drug Laws.
Many states have passed Good Samaritan laws to allow bystanders, such as family and friends, to administer naloxone to overdose victims until emergency medical services arrive.29 Some states have also started collaborative practice agreements with pharmacies to dispense naloxone. These agreements allow a practitioner to delegate a pharmacist to “initiate, modify, and monitor” naloxone therapy. In addition, many states have recently adopted statewide standing order legislation that allows pharmacists to dispense naloxone without the need for a prescription.
Helpful Resources and Additional Information for Pharmacists
Medical professionals are often missing critical toxicologic and clinical information about NPS that pose health threats from drug-drug interactions, adverse reactions, or overdose that is important in making treatment decisions.30 Although there is a wealth of information available online, it is important for pharmacists to have access to credible sources as a tool in patient education. Refer to SIDEBAR 2 for more information on new and emerging issues with NPS and acetyl fentanyl.
Occurrence and Usage. Acetylfentanyl (phenylethyl-4-piperidyl-N-phenylacetamide) is a synthetic fentanyl analogue that has been encountered as an illicit narcotic analgesic since 2013. They usually supply it as the hydrochloride salt in powders or tablets for oral administration, nasal insufflation or intravenous injection. Doses of 300–3000 μg are said to produce effects lasting 2–6 hours.
Blood Concentrations. Blood or plasma levels of acetylfentanyl in recreational users of the drug have not been reported.
Metabolism and Excretion. The fate of acetylfentanyl in mammals has not been fully evaluated. Incubation in a human liver microsomal preparation resulted in the formation of acetylnorfentanyl. Rats given a single intravenous 3 mg/kg injection developed peak urinary concentrations at 3 hours of 17 mg/L for both the parent drug and acetylnorfentanyl.
COCH3 CH2CH2 N N
COCH3 H N N
Toxicity. Excessive doses of acetylfentanyl may cause drowsiness, respiratory depression, hypotension, seizures and coma.
At least 40 deaths involving acetylfentanyl were reported in the U.S. during 2013 (MMWR, 2013; Stogner, 2014). Twenty-two adults who died due to acute overdosage with the drug had postmortem peripheral blood and urine acetylfentanyl levels of 89–945 and 41–9825 μg/L, respectively (Winecker, 2014; Cunningham et al., 2015; Finkelstein et al., 2015; McIntyre et al., 2015; Zhang
et al., 2015).
Analysis. Acetylfentanyl and acetylnorfentanyl have been quantitated in biofluids by liquid chromatography-mass spectrometry
Acetyl fentanyl is among a growing list of NPS posing significant health threats to public safety in the U.S. Regulatory challenges represent an added layer of complication in keeping these products out of the hands of the public. Pharmacists can play a fundamental role in providing education regarding risks of use of these emerging psychoactive substances as well as stand at the forefront in providing naloxone for overdose treatment.